17.14
-0.46 (-2.61%)
| Penutupan Terdahulu | 17.60 |
| Buka | 17.30 |
| Jumlah Dagangan | 52,849 |
| Purata Dagangan (3B) | 288,189 |
| Modal Pasaran | 1,016,722,496 |
| Harga / Jualan (P/S) | 145.64 |
| Harga / Buku (P/B) | 5.31 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Nov 2024 - 15 Nov 2024 |
| Margin Operasi (TTM) | -12,478.10% |
| EPS Cair (TTM) | -3.61 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 58.09% |
| Nisbah Semasa (MRQ) | 5.22 |
| Aliran Tunai Operasi (OCF TTM) | -166.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -100.20 M |
| Pulangan Atas Aset (ROA TTM) | -37.38% |
| Pulangan Atas Ekuiti (ROE TTM) | -132.11% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | IGM Biosciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 34.92% |
| % Dimiliki oleh Institusi | 63.97% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 27.00 (Stifel, 57.53%) | Beli |
| Median | 20.00 (16.69%) | |
| Rendah | 9.00 (JP Morgan, -47.49%) | Jual |
| Purata | 18.71 (9.16%) | |
| Jumlah | 5 Beli, 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 13.99 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BMO Capital | 06 Dec 2024 | 21.00 (22.52%) | Beli | 10.31 |
| Stifel | 11 Nov 2024 | 27.00 (57.53%) | Beli | 12.88 |
| RBC Capital | 18 Oct 2024 | 20.00 (16.69%) | Beli | 16.72 |
| 01 Oct 2024 | 17.00 (-0.82%) | Beli | 14.50 | |
| Guggenheim | 01 Oct 2024 | 20.00 (16.69%) | Beli | 14.50 |
| JP Morgan | 01 Oct 2024 | 9.00 (-47.49%) | Jual | 14.50 |
| Truist Securities | 01 Oct 2024 | 12.00 (-29.99%) | Pegang | 14.50 |
| Wedbush | 01 Oct 2024 | 22.00 (28.35%) | Beli | 14.50 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Nov 2024 | Pengumuman | IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update |
| 04 Nov 2024 | Pengumuman | IGM Biosciences to Present at Three Upcoming Investor Conferences |
| 30 Sep 2024 | Pengumuman | IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |